New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
15:37 EDTGILDGilead falls after recalling select lots of HIV drug
Gilead Sciences (GILD) is down about 4% in afternoon trade after the firm initiated a recall of select lots of its Atripla treatment. WHAT'S NEW: According to a post on the FDA's website, Gilead initiated a nationwide recall of of about 39,000 bottles of its Atripla treatment. Atripla is a treatment for HIV-1 infection in adults and children at least 12 years old. The recall relates to the presence of red silicone rubber particulates in the lot. ANALYST REACTION: In a note to investors following the recall, analysts at Deutsche Bank said Gilead management reiterated that the recall is a minor issue. Gilead said a typical quality check found small particles and the company proactively contacted the FDA to issue the voluntary recall of these lots. Gilead also said the recalled product comes from their 3rd party manufacturer in China that only makes this drug and noted it has multiple manufacturers for Atripla. The firm said it would be buyers on any weakness in Gilead shares following the news. Deutsche Bank maintains a Buy rating and $132 price target on shares. PRICE ACTION: In late afternoon trade, shares of Gilead are down $2.99 or 3.61%, to $79.88, though this is off the worst levels of the session.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 24, 2014
16:00 EDTGILDOptions Update; November 24, 2014
Subscribe for More Information
10:16 EDTGILDGilead management to meet with ISI Group
Meeting to be held in Scotland on December 1 hosted by ISI Group.
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 21, 2014
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN TSLA BIDU CLF DOW LVS BABA TWTR GILD
November 20, 2014
15:44 EDTGILDOptions Update; November 20, 2014
Subscribe for More Information
11:21 EDTGILDGilead calls active on renewed activist investor speculation
Gilead November 101 and 103 calls are active on 14K contracts (2K puts) on renewed activist investor speculation. November call option implied volatility is at 38, December is at 36, and January is at 35; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
11:11 EDTGILDRumor: Gilead moves up on renewed activiest investor speculation
Shares of Gilead are moving higher on speculation that Carl Icahn has taken a stake in the company.
November 19, 2014
07:33 EDTGILDGilead Q4 HCV sales likely to reach at least $3.5B, says Wells Fargo
Subscribe for More Information
November 18, 2014
16:00 EDTGILDOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
10:08 EDTGILDGilead granted European Commission marketing authorization for Harvoni
Subscribe for More Information
November 17, 2014
16:00 EDTGILDOptions Update; November 17, 2014
Subscribe for More Information
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
November 14, 2014
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
November 13, 2014
13:32 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use